Evidence map›Paper›PMID 27118243›Full record

ArticleThe Journal of antibiotics2016

Synthesis and antibacterial activity of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives.

Zhonghui Zheng, Deping Du, Lili Cao, Jun Liu, Xiaofang Chen

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhonghui ZhengShandong Xinhua Pharmaceutical Co., Ltd, Zibo City, Shandong Province, China.
Deping DuShandong Xinhua Pharmaceutical Co., Ltd, Zibo City, Shandong Province, China.
Lili CaoShandong Xinhua Pharmaceutical Co., Ltd, Zibo City, Shandong Province, China.
Jun LiuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiaofang ChenInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives (6a-h) were designed, synthesized and evaluated for their antibacterial activities in vitro. Most of these compounds had significant antibacterial activity against two groups of pathogens of Methicillin-sensitive Staphylococcus aureus (MIC

Indexed as

Anti-Bacterial AgentsAzithromycinCarbamatesErythromycinHaemophilus influenzaeKetolidesMethicillin ResistanceMicrobial Sensitivity TestsStaphylococcus aureusStaphylococcus epidermidisStreptococcus pneumoniaeStreptococcus pyogenes11-deoxy-3-des(hexopyranosyloxy)-6-O-methyl-11-(3-((3-methylphenylcarbamoyl)oxy)propylamino)-3-oxoerythromycin A 11-N,12-O-cyclic carbamate11-deoxy-3-des(hexopyranosyloxy)-6-O-methyl-11-(3-((4-nitrophenylcarbamoyl)oxy)propylamino)-3-oxoerythromycin A 11-N,12-O-cyclic carbamateAnti-Bacterial AgentsAzithromycinCarbamatescethromycinErythromycinKetolides

Identifiers

PMID27118243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.